Skopos Bio raises $8.4M seed to advance radioactive cancer therapy
What's the deal? Skopos BioDealroom has a profile for this one. Try Dealroom →, a Melbourne oncology startup, has raised US$7.76M (roughly $8.4 million) in seed funding to advance a nuclear-science-backed therapy for hard-to-treat cancers. The round was backed by three venture capital firms: Andrew Forrest's TenmileDealroom has a profile for this one. Try Dealroom →, John Wylie's Tin Alley VenturesDealroom has a profile for this one. Try Dealroom →, and Reed Jobs' YosemiteDealroom has a profile for this one. Try Dealroom →.
Who's behind it? The company was founded by three scientists from Melbourne's Peter MacCallum Cancer CentreDealroom has a profile for this one. Try Dealroom →: Michael Hofman, Luc Furic, and Mohammad Haskali. Its approach uses radioactive molecules to target and treat cancer.
What's the money for? Skopos Bio will use the funding to progress its research toward human trials.
The signal: The round pulls together some of Australia's most prominent business figures — Forrest and Wylie — alongside Yosemite, the firm run by Reed Jobs, son of Apple founder Steve Jobs. Their combined backing points to growing investor appetite for radioligand and precision oncology approaches emerging from academic research centres.
Read more: afr.com
Image credit: U.S. Department of Energy
